Table 2.
Comparison of Tirzepatide to Other Antidiabetic Agents
| Trial | Sample size (n) | Trial duration (weeks) | Tirzepatide doses (mg) | Comparator | Additional Anti-diabetic regimen | Mean treatment difference in A1c versus comparator | Mean treatment difference in weight versus placebo |
|---|---|---|---|---|---|---|---|
| SURPASS-1 | 478 | 40 |
5 10 15 |
Placebo | None |
–1∙91% (95% CI –2∙18 to –1∙63), –1∙93% (–2∙21 to –1∙65), –2∙11% (–2∙39 to –1∙83) (all P<0∙0001) |
–6∙3 kg (95% CI –7∙8 to –4∙7), –7∙1 kg (–8∙6 to –5∙5), –8∙8 kg (–10∙3 to –7∙2) (all P<0∙0001) |
| SURPASS-2 | 1,879 | 40 |
5* 10 15 |
Semaglutide 1 mg | Metformin |
−0.15 % (95% CI, −0.28 to −0.03; P=0.02), −0.39 % (−0.51 to −0.26; P<0.001), −0.45 % (−0.57 to −0.32; P<0.001) |
−1.9 kg (95% CI, −2.8 to −1.0), −3.6 kg ( −4.5 to −2.7), −5.5 kg (−6.4 to −4.6) (all P<0.001) |
| SURPASS-3 | 1,444 | 52 |
5 10 15 |
Insulin degludec | Metformin +/- SGLT2 inhibitor |
-0.59% (95% CI, -0.73 to -0.45), -0.86% (-1.00 to -0.72), -1.04% (-1.17 to -0.90), (All P<0.001) |
-9.8 kg (95% CI, -10.8 to -8.8), -13.0 kg (-14.0 to -11.9), -15.2 kg (-16.2 to -14.2), (All P < 0.001) |
| SURPASS-4 | 2,002 | 52 |
5 10 15 |
Insulin glargine | Metformin +/- sulfonylurea +/- SGLT2 inhibitor |
-0.80% (97.5% CI, -0.93 to 0.66) -0.99% (-1.13 to -0.86), -1.14% (-1.28 to -1.00), (All P < 0.001) |
-9.0 kg (95% CI, -9.8 to -8.3), -11.4 kg (-12.1 to -10.6), -13.5 kg (-14.3 to -12.8), (All P < 0.001) |
| SURPASS-5 | 475 | 40 |
5 10 15 |
Placebo | Insulin glargine +/- Metformin |
-1.30% (95% CI, -1.52 to -1.07), -1.66% (-1.88 to -1.43), -1.65% (-1.88 to -1.43), (All P < 0.001) |
-7.8 kg (95% CI, -9.4 to -6.3), -9.9 kg (-11.5 to -8.3), -12.6 kg (-14.2 to -11.0), (All P < 0.001) |
| SURPASS-6 | 1,428 | Ongoing | 5, 10, 15 | Insulin lispro | Insulin glargine +/- Metformin | Ongoing | Ongoing |